Sickle cell anemia · 9 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Hydroxyurea monotherapy Variant #01 | — | R 265 | 28d | ~1.4 mo | ~243.6 mo | ~2 | ~R 529 PFS proxy · indirect | 1 |
Crizanlizumab monotherapy Variant #01 | — | — | 14d | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Voxelotor monotherapy | — | — | — | — | — | — | — | — |
L-glutamine monotherapy Variant #01 | — | — | 336d | — | — | — | — | — |
RBC transfusions | — | — | — | — | — | — | — | — |
Exagamglogene autotemcel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
Hydroxyurea and Voxelotor Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
Observation Partial | — | — | — | ~10.3 mo | ~37.1 mo | — | — | 65 |
9 of 9 regimens shown